logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q1 2022
Summit Therapeutics plc
Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 1)
C. difficile infection
Q1 2022
Summit Therapeutics plc
Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 2)
C. difficile infection
Q1 2022
Aridis Pharmaceuticals Inc
Data from Phase IIa trial of AR-501
Cystic fibrosis
after Q1 2022
Autolus Therapeutics plc
Initial data from phase I study of AUTO4
T-cell lymphoma
2022
NovoCure
Interim analysis from phase III trial to test the efficacy and safety of TTFields (PANOVA-3)
Pancreatic adenocarcinoma
Q1 2022
Allena Pharmaceuticals, Inc.
Interim data from phase III program of Reloxaliase (URIROX-2)
Enteric hyperoxaluria
2022
Johnson & Johnson
Completion of phase I/II clinical trial of M254
Idiopathic thrombocytopenic purpura (ITP)
after Q1 2022
STEALTH BIOTHERAPEUTICS CORP
Results from phase IIb study of Elamipretide (ReCLAIM-2)
Geographic atrophy
after Q1 2022
ProQR Therapeutics
Top-line data from phase II/III trial of Sepofarsen (QR-110) ( ILLUMINATE)
Leber's congenital amaurosis 10
Q1 2022
Arena Pharmaceutical Inc.
Topline data from Phase 3 trial of Etrasimod ELEVATE UC 52
Ulcerative Colitis (UC)
Q1 2022
Arena Pharmaceutical Inc.
Topline data from Phase 3 trial of Etrasimod ELEVATE UC 12
Ulcerative Colitis (UC)
2022
9 METERS BIOPHARMA, INC.
Interim analysis from phase III trial of Larazotide
Celiac disease
after Q1 2022
Marinus Pharmaceuticals
Topline data from phase 3 study of Ganaxolone
Status Epilepticus
Early 2022
Alnylam Pharmaceuticals Inc.
Topline results from ATLAS Phase 3 program for fitusiran
Hemophilia A or B with and without inhibitors
after Q1 2022
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Imfinzi(PEARL)
First-line treatment of patients with Non-small cell lung cancer (NSCLC)
after Q1 2022
BridgeBio Pharma, Inc.
Initial data from Phase 2 dose ranging study of Low-dose infigratinib – FGFR1-3 inhibitor
Achondroplasia
2022
Calliditas Therapeutics AB (publ)
Readout of PartB of Phase 3 study of Nefecon vs placebo based on 360 patients (NefIgArd)
IgA Nephropathy
Early 2022
CTI BioPharma Corp.
Topline data from phase 3 Study of Pacritinib (PACIFICA)
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
2022
Daré Bioscience, Inc
Topline data for pivotal contraceptive study of Ovaprene
Preventing sperm from penetrating midcycle cervical mucus
2022
Innate Pharma S.A
Data from phase II trial of Lacutamab (TELLOMAK)
Sézary syndrome
2022
NuCana plc
First interim analysis from phase III study of Acelarin plus Cisplatin (NuTide:121)
Advanced biliary tract cancer
2022
Annexon, Inc.
Initial data from Phase 2 trial of ANX005
Amyotrophic lateral sclerosis (ALS)
after Q1 2022
Annexon, Inc.
Initial data from Phase 2 trial of ANX005
Warm autoimmune hemolytic anemia (wAIHA)
2022
Applied Therapeutics Inc.
Data from phase 3 Trial of AT-001 (ARISE-HF)
Diabetic Cardiomyopathy
after Q1 2022
Aptinyx Inc
Data from Phase 2b clinical study of NYX-2925
Fibromyalgia